NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Minerva Neurosciences, Inc. NERV
13 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income 1.4
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2021 · ROE -164.6%
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 |
| EBITDA $B | · | · | · | · | · | 0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | · |
| Income tax $B | · | · | · | · | −0.0 | · | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.3 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 |
| Free cash flow $B | · | · | · | −0.0 | · | · | · | · | 0.0 | · | · | −0.0 | −0.0 |
| EPS, diluted $ | −34.67 | 0.19 | −4.61 | −6.01 | −9.35 | 0.05 | −1.85 | −1.29 | −0.83 | −0.99 | −1.16 | −4.47 | −0.78 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | −164.6 | 4.8 | −122.3 | −45.2 | −26.5 | −38.5 | −50.7 | −158.8 | −16.2 |
| Shares out B | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 52 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 24 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013